

EXPRESS MAIL NO. EV335612973US

02-03-05

(f w)

# TRANSMITTAL FORM

*(To be used for all correspondence  
after initial filing)*

<b>TRANSMITTAL FORM</b>  <i>(To be used for all correspondence after initial filing)</i>	Application Number	10/606,150
	Filing Date	June 24, 2003
	First Named Inventor	Robin Callan
	Art Unit	1723
	Examiner Name	
	Attorney Docket No.	1000070.401C1

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing	Communication to TC
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Receipt	<input type="checkbox"/> Appeal Communication to
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	Board of Appeals and
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a	<input type="checkbox"/> Appeal Communication to
<input type="checkbox"/> Express Abandonment	Provisional Application	TC (Appeal Notice, Brief,
Request	<input type="checkbox"/> Power of Attorney,	Reply Brief)
<input checked="" type="checkbox"/> Information Disclosure	Revocation, Change of	<input type="checkbox"/> Proprietary Information
Statement; Form PTO-1449	Correspondence Address	<input type="checkbox"/> Status Letter
(4 Sheets)	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> 16 Cited References	<input type="checkbox"/> Statement under 37 CFR	<input type="checkbox"/> Other Enclosure(s) (please
<input type="checkbox"/> Certified Copy of Priority	3.73(b)	identify below):
Document(s)	<input type="checkbox"/> Terminal Disclaimer	<hr/> <hr/> <hr/>
<input type="checkbox"/> Response to Missing Parts	<input type="checkbox"/> Request for Refund	
under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> CD, Number	
<input type="checkbox"/> Response to Missing	of CD(s) _____	
Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	

### Remarks


**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		Customer Number
Firm Name	Seed Intellectual Property Law Group PLLC	00500
Signature		
Printed Name	Carol J. Roth	
Date	February 1, 2005	Reg. No. 32,783

**CERTIFICATE OF TRANSMISSION/MAILING**

VIA EXPRESS MAIL

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXPRESS MAIL NO. EV335612973US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robin Callan et al.  
Application No. : 10/606,150  
Filed : June 24, 2003  
For : BUFFERED COMPOSITIONS FOR DIALYSIS

Art Unit : 1723  
Docket No. : 100070.401C1  
Date : February 1, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

Carol J. Roth  
Carol J. Roth  
Registration No. 32,783

CR:ljt

Enclosures:

Postcard  
Transmittal Form  
Form PTO-1449 (4 Sheets)  
Cited References (16)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

\557087

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 100070.401C1	APPLICATION NO. 10/606,150
INFORMATION DISCLOSURE STATEMENT <small>(ATTACH additional sheets if necessary)</small>		APPLICANTS Robin Callan et al.			
		FILING DATE June 24, 2003	GROUP ART UNIT 1723		

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3962075	06/08/76	Fialkoff et al.	210	22	
	AB	4339433	07/13/82	Kartinos et al.	424	78	
	AC	4451454	05/29/84	Wong	424	127	
	AD	4500309	02/19/85	Diederich et al.	604	5	
	AE	4581141	04/08/86	Ash	210	502	
	AF	4661246	04/28/87	Ash	210	87	
	AG	4663166	05/05/87	Veech	424	146	
	AH	4756838	07/12/88	Veltman	252	1	
	AI	4784495	11/15/88	Jonsson et al.	366	151	
	AJ	4879280	11/07/89	Seyffart et al.	514	53	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	EP 457960 A	11/27/91	EPO		
	AL	EP 821951 A	02/04/98	EPO		
	AM	JP 8-92070 A	04/09/96	Japan		
	AN	JP 10-87478 A	04/07/98	Japan		X
	AO	JP 10-87478 A	04/07/98	Japan	X	

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		Gupta, A. et al., "Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis," <i>Kidney International</i> 55(5): 1891-1898, May 1999.
AQ		K ížek, M. et al., "Influence of Hemodialysis on Selenium Blood Levels," <i>Sborník lékarský</i> 101(3): 241-248, 2000.
AR		Napolitano, G. et al., "Thyroid Function and Plasma Selenium in Chronic Uremic Patients on Hemodialysis Treatment," <i>Biological Trace Element Research</i> 55(1/2): 221-230, October/November 1996.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 100070.401C1	APPLICATION NO. 10/606,150
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Robin Callan et al.			
		FILING DATE June 24, 2003	GROUP ART UNIT 1723		

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4886789	12/12/89	Milner	514	60	
	AB	4906616	03/06/90	Gilchrist et al.	514	21	
	AC	4938873	07/03/90	Rossi	210	646	
	AD	5108767	04/28/92	Mulchandani et al.	426	72	
	AE	5252213	10/12/93	Ahmad et al.	210	542	
	AF	5474992	12/12/95	Ogata et al.	514	100	
	AG	5589197	12/31/96	Shockley et al.	424	663	
	AH	5591344	01/07/97	Kenley et al.	210	636	
	AI	5624668	04/29/97	Lawrence et al.	424	78	
	AJ	5645734	07/08/97	Kenley et al.	210	805	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	WO 96/01118	01/18/96	WIPO		
	AL	WO 99/07419	02/18/99	WIPO		
	AM	WO 00/23086	04/27/00	WIPO		
	AN					
	AO					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP		Van Der Meulen, J. et al., "Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis", <i>Clinical Nephrology</i> , 37(1): 36-41, 1992.
	AQ		Zima, T. et al., "Trace Elements in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients," <i>Blood Purification</i> 16(1): 253-260, January-February 1998.
	AR		Zima, T. et al., "Trace Elements in End-Stage Renal Disease," <i>Blood Purification</i> 17(1): 187-198, 1999.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 100070.401C1	APPLICATION NO. 10/606,150
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Robin Callan et al.	
				FILING DATE June 24, 2003	GROUP ART UNIT 1723

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5651893	07/29/97	Kenley et al.	210	636	
	AB	5658456	08/19/97	Kenley et al.	210	85	
	AC	5674390	10/07/97	Matthews et al.	210	261	
	AD	5674404	10/07/97	Kenley et al.	210	741	
	AE	5690821	11/25/97	Kenley et al.	210	195	
	AF	5698100	12/16/97	Levin et al.	210	321	
	AG	5728678	03/17/98	Trimbo et al.	514	12	
	AH	5762782	06/09/98	Kenley et al.	210	85	
	AI	5780438	07/14/98	Gilchrist et al.	514	21	
	AJ	5783072	07/21/98	Kenley et al.	210	195	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		Derwent World Patent Index Database, Acc. No. 1996-235 949, Abstract of JP-A-8 092 070, Apr. 9, 1996.
AQ		“NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure,” <i>American Journal of Kidney Diseases</i> 30(4 Suppl. 3): S192-S240, October 1997.
AR		

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100070.401C1	APPLICATION NO. 10/606,150
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Robin Callan et al.	
		FILING DATE June 24, 2003	GROUP ART UNIT 1723

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5827820	10/27/98	duMoulin et al.	514	2	
	AB	5851483	12/22/98	Nicolle et al.	422	28	
	AC	5906978	05/25/99	Ash	514	23	
	AD	5945129	08/31/99	Knerr et al.	424	676	
	AE	6019925	02/01/00	Diamantoglou et al.	264	203	
	AF	6077836	06/20/00	Milner	514	54	
	AG						
	AH						
	AI						
	AJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP		
	AQ		
	AR		

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).